Literature DB >> 18083520

Docking and hydropathic scoring of polysubstituted pyrrole compounds with antitubulin activity.

Ashutosh Tripathi1, Micaela Fornabaio, Glen E Kellogg, John T Gupton, David A Gewirtz, W Andrew Yeudall, Nina E Vega, Susan L Mooberry.   

Abstract

Compounds that bind at the colchicine site of tubulin have drawn considerable attention with studies indicating that these agents suppress microtubule dynamics and inhibit tubulin polymerization. Data for 18 polysubstituted pyrrole compounds are reported, including antiproliferative activity against human MDA-MB-435 cells and calculated free energies of binding following docking the compounds into models of alphabeta-tubulin. These docking calculations coupled with HINT interaction analyses are able to represent the complex structures and the binding modes of inhibitors such that calculated and measured free energies of binding correlate with an r(2) of 0.76. Structural analysis of the binding pocket identifies important intermolecular contacts that mediate binding. As seen experimentally, the complex with JG-03-14 (3,5-dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid ethyl ester) is the most stable. These results illuminate the binding process and should be valuable in the design of new pyrrole-based colchicine site inhibitors as these compounds have very accessible syntheses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083520      PMCID: PMC2362145          DOI: 10.1016/j.bmc.2007.11.076

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  27 in total

1.  Probing the environment of tubulin-bound paclitaxel using fluorescent paclitaxel analogues.

Authors:  S Sengupta; T C Boge; Y Liu; M Hepperle; G I Georg; R H Himes
Journal:  Biochemistry       Date:  1997-04-29       Impact factor: 3.162

2.  A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach.

Authors:  Tam Luong Nguyen; Connor McGrath; Ann R Hermone; James C Burnett; Daniel W Zaharevitz; Billy W Day; Peter Wipf; Ernest Hamel; Rick Gussio
Journal:  J Med Chem       Date:  2005-09-22       Impact factor: 7.446

3.  Novel combretastatin analogues endowed with antitumor activity.

Authors:  Daniele Simoni; Romeo Romagnoli; Riccardo Baruchello; Riccardo Rondanin; Michele Rizzi; Maria Giovanna Pavani; Domenico Alloatti; Giuseppe Giannini; Marcella Marcellini; Teresa Riccioni; Massimo Castorina; Mario B Guglielmi; Federica Bucci; Paolo Carminati; Claudio Pisano
Journal:  J Med Chem       Date:  2006-06-01       Impact factor: 7.446

4.  2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents.

Authors:  Jang-Yang Chang; Ming-Fang Yang; Chi-Yen Chang; Chi-Ming Chen; Ching-Chuan Kuo; Jing-Ping Liou
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

Review 5.  Anticancer drugs from nature--natural products as a unique source of new microtubule-stabilizing agents.

Authors:  Karl-Heinz Altmann; Jürg Gertsch
Journal:  Nat Prod Rep       Date:  2007-03-08       Impact factor: 13.423

6.  Development and validation of a genetic algorithm for flexible docking.

Authors:  G Jones; P Willett; R C Glen; A R Leach; R Taylor
Journal:  J Mol Biol       Date:  1997-04-04       Impact factor: 5.469

7.  Laulimalide and synthetic laulimalide analogues are synergistic with paclitaxel and 2-methoxyestradiol.

Authors:  Erin A Clark; Patrice M Hills; Bradley S Davidson; Paul A Wender; Susan L Mooberry
Journal:  Mol Pharm       Date:  2006 Jul-Aug       Impact factor: 4.939

8.  Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells.

Authors:  P Verdier-Pinard; J Y Lai; H D Yoo; J Yu; B Marquez; D G Nagle; M Nambu; J D White; J R Falck; W H Gerwick; B W Day; E Hamel
Journal:  Mol Pharmacol       Date:  1998-01       Impact factor: 4.436

9.  Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma.

Authors:  Roisean E Ferguson; Sharon M Jackson; Anthea J Stanley; Adrian D Joyce; Patricia Harnden; Ewan E Morrison; Poulam M Patel; Roger M Phillips; Peter J Selby; Rosamonde E Banks
Journal:  Int J Cancer       Date:  2005-05-20       Impact factor: 7.396

Review 10.  Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.

Authors:  A Jordan; J A Hadfield; N J Lawrence; A T McGown
Journal:  Med Res Rev       Date:  1998-07       Impact factor: 12.944

View more
  16 in total

1.  Pyrrole-Based Antitubulin Agents: Two Distinct Binding Modalities are Predicted for C-2 Analogs in the Colchicine Site.

Authors:  Chenxiao Da; Nakul Telang; Peter Barelli; Xin Jia; John T Gupton; Susan L Mooberry; Glen E Kellogg
Journal:  ACS Med Chem Lett       Date:  2011-11-01       Impact factor: 4.345

2.  Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4.

Authors:  Lauren Lee; Lyda M Robb; Megan Lee; Ryan Davis; Hilary Mackay; Sameer Chavda; Balaji Babu; Erin L O'Brien; April L Risinger; Susan L Mooberry; Moses Lee
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

3.  Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.

Authors:  Saheem A Zaidi; Christopher K Arnatt; Hengjun He; Dana E Selley; Philip D Mosier; Glen E Kellogg; Yan Zhang
Journal:  Bioorg Med Chem       Date:  2013-09-04       Impact factor: 3.641

4.  Developing novel C-4 analogues of pyrrole-based antitubulin agents: weak but critical hydrogen bonding in the colchicine site.

Authors:  Chenxiao Da; Nakul Telang; Kayleigh Hall; Emily Kluball; Peter Barelli; Kara Finzel; Xin Jia; John T Gupton; Susan L Mooberry; Glen E Kellogg
Journal:  Medchemcomm       Date:  2013       Impact factor: 3.597

5.  Biological Characterization of an Improved Pyrrole-Based Colchicine Site Agent Identified through Structure-Based Design.

Authors:  Cristina C Rohena; Nakul S Telang; Chenxiao Da; April L Risinger; James A Sikorski; Glen E Kellogg; John T Gupton; Susan L Mooberry
Journal:  Mol Pharmacol       Date:  2015-12-11       Impact factor: 4.436

Review 6.  Hydrophobicity--shake flasks, protein folding and drug discovery.

Authors:  Aurijit Sarkar; Glen E Kellogg
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

7.  Interference with endothelial cell function by JG-03-14, an agent that binds to the colchicine site on microtubules.

Authors:  Nava Dalyot-Herman; Fernando Delgado-Lopez; David A Gewirtz; John T Gupton; Edward L Schwartz
Journal:  Biochem Pharmacol       Date:  2009-07-01       Impact factor: 5.858

8.  How to deal with low-resolution target structures: using SAR, ensemble docking, hydropathic analysis, and 3D-QSAR to definitively map the αβ-tubulin colchicine site.

Authors:  Chenxiao Da; Susan L Mooberry; John T Gupton; Glen E Kellogg
Journal:  J Med Chem       Date:  2013-09-09       Impact factor: 7.446

9.  Structure-activity relationship and in vitro and in vivo evaluation of the potent cytotoxic anti-microtubule agent N-(4-methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride and its analogues as antitumor agents.

Authors:  Aleem Gangjee; Ying Zhao; Sudhir Raghavan; Cristina C Rohena; Susan L Mooberry; Ernest Hamel
Journal:  J Med Chem       Date:  2013-08-29       Impact factor: 7.446

10.  Hydropathic analysis and biological evaluation of stilbene derivatives as colchicine site microtubule inhibitors with anti-leukemic activity.

Authors:  Ashutosh Tripathi; David Durrant; Ray M Lee; Riccardo Baruchello; Romeo Romagnoli; Daniele Simoni; Glen E Kellogg
Journal:  J Enzyme Inhib Med Chem       Date:  2009-12       Impact factor: 5.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.